z-logo
Premium
Therapeutic Effect of Irradiation of Magnetic Infrared Laser on Osteoarthritis Rat Model
Author(s) -
Moon ChulHwan,
Kwon Ogon,
Woo ChangHoon,
Ahn HeeDuk,
Kwon YoungSam,
Park SooJin,
Song ChangHyun,
Ku SaeKwang
Publication year - 2014
Publication title -
photochemistry and photobiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.818
H-Index - 131
eISSN - 1751-1097
pISSN - 0031-8655
DOI - 10.1111/php.12304
Subject(s) - osteoarthritis , diclofenac , therapeutic effect , medicine , diclofenac sodium , cartilage , adverse effect , rat model , chondrocyte , animal model , inflammation , pharmacology , pathology , anatomy , alternative medicine
Osteoarthritis ( OA ) is a degenerative joint disease caused by articular cartilage loss. Many complementary and alternative medicines for OA have been reported so far, but the effectiveness is controversial. Previously, we have shown anti‐inflammatory effects of low level laser therapy with static magnetic field, magnetic infrared laser ( MIL ), in various animal models. Therefore, the beneficial effects were examined in OA rat model. Rats were divided by six groups; no treatment controls of sham and OA model, three MIL treatment groups of OA model at 6.65, 2.66 and 1.33 J cm −2 , and D iclofenac group of OA model with 2 mg kg −1 diclofenac sodium. The OA control exhibited typical symptoms of OA , but 4‐week MIL treatment improved the functional movement of knee joint with reduced edematous changes. In addition, cartilage GAG s were detected more in all MIL treatment groups than OA control. It suggests that 4‐week MIL irradiation has dose‐dependent anti‐inflammatory and chondroprotective effects on OA . Histopathological analyses revealed that MIL treatment inhibits the cartilage degradation and enhances chondrocyte proliferation. The fact that MIL has an additional potential for the cartilage formation and no adverse effects can be regarded as great advantages for OA treatment. These suggest that MIL can be useful for OA treatment.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here